These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35091554)

  • 41. Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.
    Tenti E; Papayannidis C; Marconi G; Parisi S; Simonetti G; Paolini S; Sartor C; Ottaviani E; Testoni N; Martinelli G
    Expert Opin Pharmacother; 2016 Dec; 17(18):2479-2486. PubMed ID: 27829292
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.
    van der Helm LH; Veeger NJ; Kooy Mv; Beeker A; de Weerdt O; de Groot M; Alhan C; Hoogendoorn M; Laterveer L; van de Loosdrecht AA; Koedam J; Vellenga E; Huls G
    Leuk Res; 2013 Aug; 37(8):877-82. PubMed ID: 23628552
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcome of therapy-related myeloid neoplasms treated with azacitidine.
    Fianchi L; Criscuolo M; Lunghi M; Gaidano G; Breccia M; Levis A; Finelli C; Santini V; Musto P; Oliva EN; Leoni P; Aloe Spiriti A; D'Alò F; Hohaus S; Pagano L; Leone G; Voso MT
    J Hematol Oncol; 2012 Aug; 5():44. PubMed ID: 22853048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
    Abbas HA; Hao D; Tomczak K; Barrodia P; Im JS; Reville PK; Alaniz Z; Wang W; Wang R; Wang F; Al-Atrash G; Takahashi K; Ning J; Ding M; Beird HC; Mathews JT; Little L; Zhang J; Basu S; Konopleva M; Marques-Piubelli ML; Solis LM; Parra ER; Lu W; Tamegnon A; Garcia-Manero G; Green MR; Sharma P; Allison JP; Kornblau SM; Rai K; Wang L; Daver N; Futreal A
    Nat Commun; 2021 Oct; 12(1):6071. PubMed ID: 34663807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
    Fenaux P; Mufti GJ; Hellström-Lindberg E; Santini V; Gattermann N; Germing U; Sanz G; List AF; Gore S; Seymour JF; Dombret H; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR
    J Clin Oncol; 2010 Feb; 28(4):562-9. PubMed ID: 20026804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
    Oellerich T; Schneider C; Thomas D; Knecht KM; Buzovetsky O; Kaderali L; Schliemann C; Bohnenberger H; Angenendt L; Hartmann W; Wardelmann E; Rothenburger T; Mohr S; Scheich S; Comoglio F; Wilke A; Ströbel P; Serve H; Michaelis M; Ferreirós N; Geisslinger G; Xiong Y; Keppler OT; Cinatl J
    Nat Commun; 2019 Aug; 10(1):3475. PubMed ID: 31375673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
    Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
    Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.
    Huls G; Chitu DA; Havelange V; Jongen-Lavrencic M; van de Loosdrecht AA; Biemond BJ; Sinnige H; Hodossy B; Graux C; Kooy RVM; de Weerdt O; Breems D; Klein S; Kuball J; Deeren D; Terpstra W; Vekemans MC; Ossenkoppele GJ; Vellenga E; Löwenberg B;
    Blood; 2019 Mar; 133(13):1457-1464. PubMed ID: 30630862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
    Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
    Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
    Ivanoff S; Gruson B; Chantepie SP; Lemasle E; Merlusca L; Harrivel V; Charbonnier A; Votte P; Royer B; Marolleau JP
    Am J Hematol; 2013 Jul; 88(7):601-5. PubMed ID: 23619977
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients.
    Santaliestra M; Garrido A; Carricondo M; Bussaglia E; Pratcorona M; Blanco ML; Gich I; Hoyos M; Esquirol A; García-Cadenas I; Brunet S; Martino R; Sierra J; Nomdedéu JF
    Eur J Haematol; 2019 Sep; 103(3):208-214. PubMed ID: 31211880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of hypomethylating agents in the treatment of elderly patients with AML.
    Al-Ali HK; Jaekel N; Niederwieser D
    J Geriatr Oncol; 2014 Jan; 5(1):89-105. PubMed ID: 24484723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Azacitidine treatment for acute myeloid leukemia with myelodysplasia-related changes during peritoneal dialysis].
    Omatsu T; Udaka K; Shibata H; Sekimoto E; Ozaki S
    Rinsho Ketsueki; 2017; 58(12):2369-2374. PubMed ID: 29332868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
    Dombret H; Seymour JF; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Bernal del Castillo T; Al-Ali HK; Martinelli G; Falantes J; Noppeney R; Stone RM; Minden MD; McIntyre H; Songer S; Lucy LM; Beach CL; Döhner H
    Blood; 2015 Jul; 126(3):291-9. PubMed ID: 25987659
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
    Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
    Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.
    Ozbalak M; Cetiner M; Bekoz H; Atesoglu EB; Ar C; Salihoglu A; Tuzuner N; Ferhanoglu B
    Hematol Oncol; 2012 Jun; 30(2):76-81. PubMed ID: 21387357
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.
    Font P
    Adv Ther; 2011 Mar; 28 Suppl 3():1-9. PubMed ID: 21431628
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia.
    Tamura A; Ishida T; Saito A; Yamamoto N; Yokoi T; Uemura S; Nino N; Fujiwara T; Tahara T; Nakamura S; Kozaki A; Kishimoto K; Hasegawa D; Kosaka Y
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27284. PubMed ID: 29893458
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.